US Residual DNA Testing Market (2025-2030)
The US Residual DNA Testing Market was valued at $57.7 Million in 2025 and projected to reach to $75.8 Million by 2030, representing a compound annual growth rate of 5.6%. The US residual DNA testing market is poised for steady growth through 2030, driven by increasing pharmaceutical manufacturing complexity and heightened regulatory scrutiny.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US Residual DNA Testing Market Trends and Insights
- In the US, residual DNA testing has become increasingly critical for pharmaceutical manufacturing, forensic analysis, and clinical diagnostics, driven by stringent regulatory requirements and quality assurance protocols.
- The US market reflects steady adoption across healthcare and life sciences sectors, supported by advanced laboratory infrastructure and compliance-focused operations. US residual DNA testing demand is fueled by the pharmaceutical industry's need to ensure product safety and meet FDA guidelines for manufacturing processes.
- The US healthcare system's emphasis on precision medicine and contamination detection continues to drive market expansion through 2030.
- Growth in the US is more measured compared to global trends, reflecting mature market dynamics and established regulatory frameworks that prioritize quality over rapid scaling..
Key Market Statistics
- CAGR (2025-2030) 5.6% CAGR
- Market Size, 2025 ~USD 57.7 Million
- Forecast, 2030 ~USD 75.8 Million
- Country US
US Residual DNA Testing Market Overview
Market Valuation :
The US residual DNA testing market is valued at $57.7 million in 2025, with projected growth to $75.8 million by 2030, representing a steady 5.6% CAGR driven by pharmaceutical and diagnostic sector expansion.
Regulatory Compliance Driver :
Stringent FDA and ICH guidelines mandate residual DNA testing in pharmaceutical manufacturing, making compliance a primary growth catalyst for US-based biotech and pharmaceutical companies.
Multi-Sector Application :
US market adoption spans pharmaceutical manufacturing, forensic analysis, and clinical diagnostics, with pharmaceutical quality assurance representing the largest revenue segment.
Growth Trajectory :
At 5.6% CAGR, the US market grows slower than the global average of 16.4%, indicating market maturity but sustained demand from established pharmaceutical and biotech industries.
US Residual DNA Testing Market Dynamics
- Biopharmaceutical companies are investing in advanced testing technologies to ensure product safety and meet FDA compliance standards.
- The market benefits from established quality assurance protocols and a mature healthcare infrastructure. Future expansion will be supported by growing adoption in cell and gene therapy manufacturing, where residual DNA testing is critical for patient safety.
- Consolidation among testing service providers and technological innovations in detection methods will enhance market competitiveness.
- The US market's slower growth compared to global rates reflects market saturation among established players, with opportunities emerging in emerging therapeutic areas and contract manufacturing organizations..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Thermo Fisher Scientific Inc.
- Merck KGaA
- SANOFI
- Pfizer Inc.
- NOVARTIS
Key Takeaways
- The US residual DNA testing market is valued at $57.7 million in 2025 and will reach $75.8 million by 2030 at a 5.6% CAGR.
- US pharmaceutical manufacturers drive demand through FDA compliance and quality assurance requirements for residual DNA detection.
- The US market benefits from mature laboratory infrastructure and established regulatory frameworks supporting steady, sustainable growth.
- US healthcare's focus on precision medicine and contamination prevention sustains market expansion through the forecast period.
Residual DNA Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | CELL & GENE THERAPY (Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 16.4% from 2025 to 2030 |
| Largest Segment | POLYMERASE CHAIN REACTION (Technology) |
| Market Size Base Year (Billions) | ~USD 0.17 (2025) |
| Revenue Forecast (Billions) | ~USD 0.37 (2030) |
| Segments Covered | Offering, Type, Test Type, Technology, Application, End User |
US Residual DNA Testing Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Consumables
- Instruments & Software
By Test Type
- Bulk Lot Release Testing
- Final Product Release Testing
- Raw Material Testing
By Technology
- Dna Probe Hybridization
- Other Technologies
- Polymerase Chain Reaction
- Threshold Assays
By Application
- Cell & Gene Therapy
- Monoclonal Antibodies
- Other Applications
- Vaccines
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Pharmaceutical & Biopharmaceutical Companies
- Pharmaceutical & Biotechnology Companies
US: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 5.2 | 5.3 | 5.4 | 5.5 | 5.7 | 5.9 | 6.1 | 6.4 | 3.5 |
| CROS & CDMOS | 10.6 | 10.9 | 11.3 | 11.7 | 12.2 | 12.9 | 13.7 | 14.6 | 5.3 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 38 | 39.4 | 41 | 42.9 | 45.2 | 47.9 | 51.1 | 54.8 | 6 |
| TOTAL | 53.8 | 55.5 | 57.7 | 60.2 | 63.1 | 66.6 | 70.8 | 75.8 | 5.6 |
US: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 9.8 | 10.3 | 10.9 | 11.5 | 12.2 | 13 | 13.8 | 14.8 | 6.4 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 25.5 | 27.1 | 29 | 31 | 33.2 | 35.7 | 38.5 | 41.6 | 7.5 |
| TOTAL | 35 | 37 | 40 | 43 | 45 | 49 | 52 | 56 | 7.2 |
Target Audience
- Pharmaceutical Manufacturers : US-based pharma companies require residual DNA testing market insights to optimize quality assurance budgets, select testing partners, and ensure FDA compliance in manufacturing operations.
- Biotech & Gene Therapy Companies : Emerging biotech firms need detailed US market data to understand testing requirements, benchmark costs, and plan regulatory strategies for cell and gene therapy product development.
- Contract Research Organizations (CROs) : CROs and contract manufacturing organizations require market intelligence to expand residual DNA testing service portfolios and identify client acquisition opportunities in the US market.
- Diagnostic & Testing Service Providers : Testing laboratories and diagnostic companies need US-specific market forecasts to guide service expansion, technology investment, and competitive positioning in pharmaceutical and forensic segments.
- Healthcare Investors & Consultants : Investment firms and management consultants require accurate US market data to evaluate acquisition targets, assess portfolio companies, and identify growth opportunities in healthcare diagnostics.
Key Companies in the US Residual DNA Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Consumables (assay kits, reagents, plastics),Instruments (PCR, qPCR, automation),Software & informatics, |
| CHARLES RIVER LABORATORIES | United States | Public Company | Consumables (assay reagents, kits within services),Instruments & Software (PCR and data platforms used in labs),Services – Raw Material Testing, |
| MERCK KGAA | United States | Public Company | Consumables (reagents, kits, assay components),Instruments,Software & Services (including CDMO/CRO testing support), |
| MARAVAI LIFESCIENCES | United States | Public Company | Consumables,Instrument & Software,Services, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Consumables,Instrument & Software,PCR-based Testing Services, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Consumables,Instruments,Software & Informatics, |
| QIAGEN | Netherlands | Public Company | Consumables (sample prep, PCR, assays),Instruments (PCR, sample prep, QC),Software & Bioinformatics, |
| FUJIFILM CORPORATION | Japan | Public Company | Consumables (reagents, kits, media-linked components),Instruments & Software (PCR platforms, analytics, workflow tools),PCR-based Testing Services (CDMO-integrated), |
| SGS SOCIÉTÉ GéNéRALE DE SURVEILLANCE SA. | Switzerland | Public Company | Consumables-linked testing services,Instrument & software-enabled testing services,PCR-based residual DNA testing (all test types), |
| REVVITY | United States | Public Company | Consumables (reagents, assay kits, cartridges),Instruments,Software & Services, |
| INTERTEK GROUP PLC | United Kingdom | Public Company | Consumables,Instruments & Software,PCR-based Testing Services, |
| SARTORIUS AG | United States | Public Company | Consumables (filters, reagents, lab plastics linked to residual DNA workflows),Instruments (bioreactors, filtration systems, analytical platforms used in DNA-controlled processes),Software & data analytics (lab data, PAT, and QC integration), |
| LONZA | Switzerland | Public Company | Consumables,Instruments & Software,PCR-based Testing Services, |
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a leading global provider of life sciences solutions, founded in 1956 and headquartered in the United States. With 125,000 employees, the company operates as a public corporation serving research, diagnostics, and bioproduction markets worldwide.
CHARLES RIVER LABORATORIES
Charles River Laboratories is a contract research organization founded in 1947, providing preclinical and clinical laboratory services to the pharmaceutical and biotechnology industries. The U.S.-based public company employs 19,000 people and supports drug development and safety testing globally.
MERCK KGAA
Merck KGaA is a diversified science and technology company founded in 1668, operating as a public company with 59,077 employees across the United States and globally. The company serves the pharmaceutical, life sciences, and performance materials sectors.
MARAVAI LIFESCIENCES
Maravai LifeSciences is a U.S.-based public company founded in 2014, specializing in critical reagents and services for the life sciences industry. With 416 employees, the company supports vaccine development, gene therapy, and molecular diagnostics.
EUROFINS SCIENTIFIC
Eurofins Scientific is a Luxembourg-based public company founded in 1987, operating a global network of laboratories with 65,694 employees. The company provides testing and analytical services across pharmaceutical, food, environmental, and consumer product sectors.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a U.S. public company founded in 1952, manufacturing and distributing life science research and clinical diagnostics products. With 7,450 employees, the company serves research institutions, hospitals, and laboratories worldwide.
QIAGEN
QIAGEN is a Netherlands-based public company founded in 1984, specializing in sample and assay technologies for molecular diagnostics and life sciences research. The company employs 5,500 people and serves clinical, pharmaceutical, and academic markets globally.
FUJIFILM CORPORATION
Fujifilm Corporation is a Japanese multinational public company founded in 1934, with 73,526 employees operating across imaging, information, and life sciences divisions. The company provides diagnostic imaging, pharmaceutical, and biotechnology solutions worldwide.
SGS SOCIÉTÉ GéNéRALE DE SURVEILLANCE SA.
SGS Société Générale de Surveillance SA. is a Switzerland-based public company founded in 1878, employing 83,000 people in inspection, verification, testing, and certification services. The company serves industries including pharmaceuticals, food, and consumer goods globally.
REVVITY
Revvity is a U.S.-based public company founded in 1937, providing analytical instruments, software, and services for research and diagnostics. With 11,000 employees, the company supports life sciences, diagnostics, and environmental testing applications.
INTERTEK GROUP PLC
Intertek Group PLC is a United Kingdom-based public company founded in 1885, employing 45,425 people in testing, inspection, and certification services. The company serves industries including pharmaceuticals, chemicals, and consumer products across the globe.
SARTORIUS AG
Sartorius AG is a U.S.-based public company founded in 1870, manufacturing laboratory and bioprocess equipment with 14,242 employees. The company provides filtration, weighing, and bioanalytical solutions for pharmaceutical and life sciences applications.
LONZA
Lonza is a Switzerland-based public company founded in 1897, employing 20,000 people in pharmaceutical and biotechnology manufacturing and services. The company specializes in custom development and manufacturing, cell therapy, and specialty ingredients.
Reasons to Buy this Report
- Regulatory Compliance Intelligence : Understand FDA and ICH requirements driving US pharmaceutical companies' investment in residual DNA testing, enabling strategic compliance planning and market positioning.
- Competitive Market Sizing : Access precise US market valuation ($57.7M in 2025) and growth projections to benchmark against competitors and identify market share opportunities in pharmaceutical and forensic segments.
- Sector-Specific Insights : Gain detailed analysis of pharmaceutical manufacturing, forensic analysis, and clinical diagnostics applications unique to the US market, informing product development and service offerings.
- Investment Decision Support : Leverage 5-year forecast data and CAGR analysis to evaluate market attractiveness, identify growth pockets, and make informed capital allocation decisions for US operations.
- Strategic Partnership Opportunities : Identify high-growth segments and emerging therapeutic areas (cell/gene therapy) where partnerships with testing providers and pharmaceutical manufacturers can drive revenue expansion.
Frequently asked questions
What is the current size of the US residual DNA testing market?
The US residual DNA testing market is valued at $57.7 million in 2025 and is expected to grow to $75.8 million by 2030.
What is the growth rate of the US residual DNA testing market?
The US residual DNA testing market is growing at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2030.
What drives demand for residual DNA testing in the US?
US demand is driven by FDA compliance requirements, pharmaceutical manufacturing quality assurance, forensic applications, and the healthcare industry's emphasis on contamination detection and product safety.
Which industries use residual DNA testing in the US?
The US residual DNA testing market serves pharmaceutical manufacturing, clinical diagnostics, forensic laboratories, biotechnology firms, and contract research organizations focused on quality control.
How does the US market compare to global residual DNA testing growth?
The US market grows at 5.6% CAGR, which is more moderate than the global CAGR of 16.4%, reflecting a mature, regulated market with established quality standards.
RESEARCH METHODOLOGY
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global residual DNA testing market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, World Health Organization (WHO), United States Food and Drug Administration (US FDA), National Center for Biotechnology Information (NCBI), Health Canada, European Medicines Agency (EMA), and Centers for Disease Control and Prevention (CDC). These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative & quantitative information and assess the prospects of the market. Various primary sources from both the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the residual DNA testing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
The total market was split into several segments and subsegments after arriving at the overall market size from the estimation process. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Residual DNA testing involves the detection and quantification of DNA impurities from host cells present in biopharmaceutical products. This testing is a critical component in the quality assurance of biologics, as it assesses the levels of residual DNA that may remain in the final product, bulk intermediates, or raw materials post-purification. The market for residual DNA testing encompasses a diverse array of analytical tools and services tailored to meet stringent regulatory requirements. Compliance with guidelines established by the FDA, WHO, and GxP standards necessitates a thorough evaluation of host cell DNA to mitigate risks and ensure safety and efficacy in biologics. This regulatory landscape makes residual DNA testing a vital focus area in the development and manufacturing of biologic products, emphasizing the need for precision and reliability in these assessments.
Stakeholders
- Pharmaceutical & biotechnology companies
- Academic researchers and government research organizations
- Private research institutes
- Custom residual DNA testing service providers
- Contract development & manufacturing organizations (CDMOs)
- Life Science Companies
- Contract research organizations (CROs)
- Market research & consulting firms
- Venture capitalists
Report Objectives
- To define, describe, and forecast the global residual DNA testing market by offering, technology, test type, application, end user (product), end user (service), and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall residual DNA testing market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- Track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the residual DNA testing market.
- To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the residual DNA testing market.
Get the Full Residual DNA Testing Market Report
Full forecast, segment splits, and company analysis for all Residual DNA Testing Market.
- Canada Residual DNA Testing Market
- Germany Residual DNA Testing Market
- UK Residual DNA Testing Market
- France Residual DNA Testing Market
- Italy Residual DNA Testing Market
- Spain Residual DNA Testing Market
- China Residual DNA Testing Market
- Japan Residual DNA Testing Market
- India Residual DNA Testing Market
- South Korea Residual DNA Testing Market
- Australia Residual DNA Testing Market
- Brazil Residual DNA Testing Market
- Mexico Residual DNA Testing Market
- UAE Residual DNA Testing Market
- Rest Of Europe Residual DNA Testing Market
- Rest Of Asia Pacific Residual DNA Testing Market
- Rest Of Latin America Residual DNA Testing Market
- Rest Of GCC Countries Residual DNA Testing Market
- Saudi Arabia Residual DNA Testing Market
- GCC Countries Residual DNA Testing Market
- Rest Of Middle East Residual DNA Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
